Mdxhealth Sa (MXDHF) 4.9800 $MXDHF
MDxHealth's ConfirmMDx for Prostate Cancer Test Qualifies for Medicare Coverage Effective November 3, 2014
GlobeNewswire - Tue Sep 23, 1:19AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that its ConfirmMDx for Prostate Cancer test qualifies for Medicare coverage effective November 3, 2014.
MDxHealth to Participate in the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Mon Sep 08, 9:33AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will participate in the Rodman & Renshaw 16th Annual Global Investment Conference in New York, NY.
MDxHealth Reports First Half Year 2014 Results
GlobeNewswire - Thu Aug 21, 1:12AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results of the first-half year ended June 30, 2014.
MDxHealth ConfirmMDx Biomarker Associated with the Risk of Recurrence for Early Stage Prostate Cancer Patients
GlobeNewswire - Mon Aug 18, 1:07AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that one of the ConfirmMDx for Prostate Cancer epigenetic genes is independently associated with risk of recurrence in patients with early prostate cancer (PCa). The results from this study, published in The Journal of Urology [The Journal of Urology (2014), doi: 10.1016/j.juro.2014.04.082], suggest that epigenetic analysis could play a clinical role in identifying patients who have a slow growing cancer eligible for active surveillance from those with a higher risk of recurrence who may benefit from a more aggressive therapeutic approach.
MDxHealth Signs Two New Insurance Agreements Providing Increased Access to ConfirmMDx for Prostate Cancer
GlobeNewswire - Thu Aug 14, 1:07AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has signed agreements with Ancillary Care Services (ACS), a subsidiary of American CareSource Holdings Inc. and separately, Consilium, LLC. ACS offers its providers quality and cost-effective healthcare services through their managed care network agreements covering 4.5 million lives. Consilium is a complete solution provider for out-of-network healthcare claims. The agreements provide patients access to MDxHealth's ConfirmMDx for Prostate Cancer test.
MDxHealth (R) : MDxHealth Licensee Exact Sciences Receives FDA Approval for its Cologuard Colon Cancer Screening Assay
GlobeNewswire - Tue Aug 12, 2:05AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the U.S. Food and Drug Administration's (FDA) has approved Exact Sciences' Cologuard(R) stool-DNA-based, non-invasive colorectal cancer screening test. The test incorporates one of MDxHealth's epigenetic biomarkers, which was licensed to Exact Sciences in July 2010. Upon product launch, anticipated before the end of 2014, MDxHealth expects to receive milestone payments and royalties from the sale of the test under the terms of its licensing agreement.
ConfirmMDx Studies Highlighted by Elsevier, Publisher of The Journal of Urology(r)
GlobeNewswire - Tue Jul 22, 1:08AM CDT
Underscores Importance of Recent Confirmatory Clinical Validation Results Leading to Medicare Reimbursement Milestone
MDxHealth and Miraca Life Sciences Announce Agreement to Promote ConfirmMDx for Prostate Cancer
GlobeNewswire - Wed Jul 02, 1:06AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has entered into an agreement with Miraca Life Sciences (MLS), the nation's largest independent anatomic pathology lab, to promote MDxHealth's ConfirmMDx for Prostate Cancer test. Serving more than 5,500 patients each day, Miraca Life Sciences is a national leader in providing academic-caliber pathology services in the fields of dermatology, hematology, gastroenterology and urology.
MDxHealth and LI PATH Announce Marketing Agreement for ConfirmMDx for Prostate Cancer
GlobeNewswire - Wed Apr 02, 1:11AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has entered into a co-marketing agreement with LI PATH (Long Island Pathology, Inc.) to promote MDxHealth's ConfirmMDx for Prostate Cancer test. LI PATH is a high-end, full-service independent anatomic and clinical pathology laboratory that serves the New York City metropolitan area. The agreement expands MDxHealth's access to urologists in the highly populated New York and New Jersey region.
MDxHealth Licensee Exact Sciences Receives FDA Panel Recommendation for Approval of Colorectal Cancer Screening Test
GlobeNewswire - Fri Mar 28, 2:13AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the Molecular and Clinical Genetics Panel of the United States Food and Drug Administration's (FDA) Medical Devices Advisory Committee strongly endorsed approval of Cologuard(TM). The Committee determined by a unanimous vote of 10 to zero that Exact Sciences has demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard, the company's stool-based DNA (sDNA), non-invasive colorectal cancer screening test. Cologuard incorporates one of MDxHealth's epigenetic biomarkers and methylation specific PCR (MSP) technology, which was licensed to Exact Sciences in July 2010.
Predictive Diagnostics - Global Strategic Business Report
M2 - Tue Mar 18, 7:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvpvwm/predictive) has announced the addition of the "Predictive Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Predictive Diagnostics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 58 companies including many key and niche players such as: - Abbott Molecular - Almac Group Ltd. - BioGenex - Covance, Inc. - Dako Denmark A/S - Epistem Plc - F. Hoffmann-La Roche Ltd. - Genomic Health, Inc. - MDxHEALTH, Inc. - Myriad Genetics, Inc. - Precision Therapeutics, Inc. - Prometheus Laboratories - QIAGEN N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. Executive Summary 1. INDUSTRY OVERVIEW 2. MAJOR MARKET TRENDS, DRIVERS & ISSUES 3. PRODUCT OVERVIEW 4. RECENT INDUSTRY ACTIVITY 5. FOCUS ON SELECT PLAYERS 6. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 58 (including Divisions/Subsidiaries - 61) - The United States (31) - Canada (2) - Europe (19) - Germany (4) - The United Kingdom (7) - Spain (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (7) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/dvpvwm/predictive
MDxHealth's PredictMDx for Glioblastoma Identifies Newly Diagnosed Patients with Improved Progression Free and Overall Survival
GlobeNewswire - Tue Mar 04, 1:11AM CST
Results of Phase III Trial for Bevacizumab (Avastin(R)) Published in the New England Journal of Medicine
MDxHealth Reports Fourth Quarter and Fiscal Year 2013 Results
GlobeNewswire - Thu Feb 27, 1:05AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results for the fourth quarter and the fiscal year ended December 31, 2013. This year the company has changed its reporting currency to U.S. Dollars, while keeping its functional currency in Euros.
ConfirmMDx for Prostate Cancer Test Featured in ONCOLOGY
GlobeNewswire - Mon Feb 24, 1:07AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the ConfirmMDx for Prostate Cancer test was highlighted as one of several key advances in biomarker technology that aims to transform detection of prostate cancer and its subsequent management. In a review published in the February 2014 issue of ONCOLOGY, leading urologists, E. David Crawford, MD, Neal D. Shore, MD and co-author Karen Ventii, PhD, explain how an explosion in genomic analysis and interpretation of prostate cancer tissue has enabled discovery of new biomarkers, their integration into clinical practice, and clinical management of the disease.
MDxHealth Secures Agreement with Prime Health Services PPO Network Providing Increased Access to ConfirmMDx for Prostate Cancer
GlobeNewswire - Thu Feb 20, 1:10AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has signed an agreement with Prime Health Services, Inc. ("Prime Health"
a Preferred Provider Organization (PPO) network. This agreement covers all 50 states, offering patients greater access to MDxHealth's ConfirmMDx(R) for Prostate Cancer test. This agreement extends ConfirmMDx for Prostate Cancer testing to approximately 144 million covered lives throughout the U.S.
MDxHealth's ConfirmMDx(R) for Prostate Cancer Epigenetic Test Correctly Identifies Prostate Cancer Missed in Five Previous Biopsies
GlobeNewswire - Wed Feb 12, 1:09AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the ConfirmMDx for Prostate Cancer test was used as part of an multidisciplinary approach to successfully confirm prostate cancer diagnosis missed by five previous biopsies. The case study of a 63-year old man was published online in The Journal of OncoPathology (La Rosa FG, Jones C, Arangua P, Crawford ED & Van Neste L (2013). Finding Occult Prostatic Cancer: The Value of Transperineal Mapping Biopsies and Epigenetic Assays http://www.ingentaconnect.com/content/oc/tjop...jop100078) by researchers from the University of Colorado (USA) and Maastricht University Medical Center (Netherlands).
MDxHealth's ConfirmMDx Genes Identify Aggressive Prostate Cancer
GlobeNewswire - Mon Feb 03, 1:16AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced positive results from an important study designed to identify patients with aggressive prostate cancer (PCa). The study, presented at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, USA (January 30 - February 1, 2014), confirmed that epigenetic profiling of selected genes provides prognostic information, corresponding to Gleason score (GS), that could help to identify patients with aggressive PCa.
MDxHealth to Present Results from Epigenetic Prostate Test to Identify Aggressive Prostate Cancer at the ASCO Genitourinary Cancers Symposium 2014
GlobeNewswire - Wed Jan 29, 1:08AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will present results from an important study involving the development of their prostate cancer (PCa) aggressiveness test at the ASCO Genitourinary Cancers Symposium 2014 in San Francisco, California, USA (January 30 - February 1, 2014).
MDxHealth Announces Agreement with Teva Pharmaceuticals for Commercialization of Two Cancer Tests in Israel
GlobeNewswire - Thu Jan 23, 4:14AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has signed an exclusive agreement with Teva Pharmaceuticals Ltd. for commercialization of ConfirmMDx for Prostate Cancer and PredictMDx for Glioblastoma tests in Israel. ConfirmMDx provides physicians with actionable information that helps improve patient care, particularly the avoidance of unnecessary repeat prostate biopsies. The PredictMDx test is used to identify glioma patients who have methylation of the MGMT (O6-Methylguanine-DNA Methyltransferase) gene. In clinical studies, these patients have shown the potential to respond better to certain chemotherapeutic drugs.
MDxHealth Signs Agreement With Stratose(R) to Expand Insurance Coverage for ConfirmMDxTM for Prostate Cancer Test
Marketwire - Tue Sep 03, 1:31AM CDT
MDxHealth SA (EURONEXT BRUSSELS: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, today announced that it has entered into an agreement with Stratose, one of the largest healthcare PPO network providers in the U.S. The agreement provides Stratose's 12.4 million member network with access to ConfirmMDx for Prostate Cancer testing.
MDxHealth's ConfirmMDx for Prostate Cancer Test Qualifies for Medicare Coverage Effective November 3, 2014
GlobeNewswire - Tue Sep 23, 1:19AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that its ConfirmMDx for Prostate Cancer test qualifies for Medicare coverage effective November 3, 2014.
MDxHealth to Participate in the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Mon Sep 08, 9:33AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will participate in the Rodman & Renshaw 16th Annual Global Investment Conference in New York, NY.
MDxHealth Reports First Half Year 2014 Results
GlobeNewswire - Thu Aug 21, 1:12AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results of the first-half year ended June 30, 2014.
MDxHealth ConfirmMDx Biomarker Associated with the Risk of Recurrence for Early Stage Prostate Cancer Patients
GlobeNewswire - Mon Aug 18, 1:07AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that one of the ConfirmMDx for Prostate Cancer epigenetic genes is independently associated with risk of recurrence in patients with early prostate cancer (PCa). The results from this study, published in The Journal of Urology [The Journal of Urology (2014), doi: 10.1016/j.juro.2014.04.082], suggest that epigenetic analysis could play a clinical role in identifying patients who have a slow growing cancer eligible for active surveillance from those with a higher risk of recurrence who may benefit from a more aggressive therapeutic approach.
MDxHealth Signs Two New Insurance Agreements Providing Increased Access to ConfirmMDx for Prostate Cancer
GlobeNewswire - Thu Aug 14, 1:07AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has signed agreements with Ancillary Care Services (ACS), a subsidiary of American CareSource Holdings Inc. and separately, Consilium, LLC. ACS offers its providers quality and cost-effective healthcare services through their managed care network agreements covering 4.5 million lives. Consilium is a complete solution provider for out-of-network healthcare claims. The agreements provide patients access to MDxHealth's ConfirmMDx for Prostate Cancer test.
MDxHealth (R) : MDxHealth Licensee Exact Sciences Receives FDA Approval for its Cologuard Colon Cancer Screening Assay
GlobeNewswire - Tue Aug 12, 2:05AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the U.S. Food and Drug Administration's (FDA) has approved Exact Sciences' Cologuard(R) stool-DNA-based, non-invasive colorectal cancer screening test. The test incorporates one of MDxHealth's epigenetic biomarkers, which was licensed to Exact Sciences in July 2010. Upon product launch, anticipated before the end of 2014, MDxHealth expects to receive milestone payments and royalties from the sale of the test under the terms of its licensing agreement.
ConfirmMDx Studies Highlighted by Elsevier, Publisher of The Journal of Urology(r)
GlobeNewswire - Tue Jul 22, 1:08AM CDT
Underscores Importance of Recent Confirmatory Clinical Validation Results Leading to Medicare Reimbursement Milestone
MDxHealth and Miraca Life Sciences Announce Agreement to Promote ConfirmMDx for Prostate Cancer
GlobeNewswire - Wed Jul 02, 1:06AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has entered into an agreement with Miraca Life Sciences (MLS), the nation's largest independent anatomic pathology lab, to promote MDxHealth's ConfirmMDx for Prostate Cancer test. Serving more than 5,500 patients each day, Miraca Life Sciences is a national leader in providing academic-caliber pathology services in the fields of dermatology, hematology, gastroenterology and urology.
MDxHealth and LI PATH Announce Marketing Agreement for ConfirmMDx for Prostate Cancer
GlobeNewswire - Wed Apr 02, 1:11AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has entered into a co-marketing agreement with LI PATH (Long Island Pathology, Inc.) to promote MDxHealth's ConfirmMDx for Prostate Cancer test. LI PATH is a high-end, full-service independent anatomic and clinical pathology laboratory that serves the New York City metropolitan area. The agreement expands MDxHealth's access to urologists in the highly populated New York and New Jersey region.
MDxHealth Licensee Exact Sciences Receives FDA Panel Recommendation for Approval of Colorectal Cancer Screening Test
GlobeNewswire - Fri Mar 28, 2:13AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the Molecular and Clinical Genetics Panel of the United States Food and Drug Administration's (FDA) Medical Devices Advisory Committee strongly endorsed approval of Cologuard(TM). The Committee determined by a unanimous vote of 10 to zero that Exact Sciences has demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard, the company's stool-based DNA (sDNA), non-invasive colorectal cancer screening test. Cologuard incorporates one of MDxHealth's epigenetic biomarkers and methylation specific PCR (MSP) technology, which was licensed to Exact Sciences in July 2010.
Predictive Diagnostics - Global Strategic Business Report
M2 - Tue Mar 18, 7:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvpvwm/predictive) has announced the addition of the "Predictive Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Predictive Diagnostics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 58 companies including many key and niche players such as: - Abbott Molecular - Almac Group Ltd. - BioGenex - Covance, Inc. - Dako Denmark A/S - Epistem Plc - F. Hoffmann-La Roche Ltd. - Genomic Health, Inc. - MDxHEALTH, Inc. - Myriad Genetics, Inc. - Precision Therapeutics, Inc. - Prometheus Laboratories - QIAGEN N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. Executive Summary 1. INDUSTRY OVERVIEW 2. MAJOR MARKET TRENDS, DRIVERS & ISSUES 3. PRODUCT OVERVIEW 4. RECENT INDUSTRY ACTIVITY 5. FOCUS ON SELECT PLAYERS 6. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 58 (including Divisions/Subsidiaries - 61) - The United States (31) - Canada (2) - Europe (19) - Germany (4) - The United Kingdom (7) - Spain (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (7) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/dvpvwm/predictive
MDxHealth's PredictMDx for Glioblastoma Identifies Newly Diagnosed Patients with Improved Progression Free and Overall Survival
GlobeNewswire - Tue Mar 04, 1:11AM CST
Results of Phase III Trial for Bevacizumab (Avastin(R)) Published in the New England Journal of Medicine
MDxHealth Reports Fourth Quarter and Fiscal Year 2013 Results
GlobeNewswire - Thu Feb 27, 1:05AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results for the fourth quarter and the fiscal year ended December 31, 2013. This year the company has changed its reporting currency to U.S. Dollars, while keeping its functional currency in Euros.
ConfirmMDx for Prostate Cancer Test Featured in ONCOLOGY
GlobeNewswire - Mon Feb 24, 1:07AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the ConfirmMDx for Prostate Cancer test was highlighted as one of several key advances in biomarker technology that aims to transform detection of prostate cancer and its subsequent management. In a review published in the February 2014 issue of ONCOLOGY, leading urologists, E. David Crawford, MD, Neal D. Shore, MD and co-author Karen Ventii, PhD, explain how an explosion in genomic analysis and interpretation of prostate cancer tissue has enabled discovery of new biomarkers, their integration into clinical practice, and clinical management of the disease.
MDxHealth Secures Agreement with Prime Health Services PPO Network Providing Increased Access to ConfirmMDx for Prostate Cancer
GlobeNewswire - Thu Feb 20, 1:10AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has signed an agreement with Prime Health Services, Inc. ("Prime Health"
a Preferred Provider Organization (PPO) network. This agreement covers all 50 states, offering patients greater access to MDxHealth's ConfirmMDx(R) for Prostate Cancer test. This agreement extends ConfirmMDx for Prostate Cancer testing to approximately 144 million covered lives throughout the U.S. MDxHealth's ConfirmMDx(R) for Prostate Cancer Epigenetic Test Correctly Identifies Prostate Cancer Missed in Five Previous Biopsies
GlobeNewswire - Wed Feb 12, 1:09AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the ConfirmMDx for Prostate Cancer test was used as part of an multidisciplinary approach to successfully confirm prostate cancer diagnosis missed by five previous biopsies. The case study of a 63-year old man was published online in The Journal of OncoPathology (La Rosa FG, Jones C, Arangua P, Crawford ED & Van Neste L (2013). Finding Occult Prostatic Cancer: The Value of Transperineal Mapping Biopsies and Epigenetic Assays http://www.ingentaconnect.com/content/oc/tjop...jop100078) by researchers from the University of Colorado (USA) and Maastricht University Medical Center (Netherlands).
MDxHealth's ConfirmMDx Genes Identify Aggressive Prostate Cancer
GlobeNewswire - Mon Feb 03, 1:16AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced positive results from an important study designed to identify patients with aggressive prostate cancer (PCa). The study, presented at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, USA (January 30 - February 1, 2014), confirmed that epigenetic profiling of selected genes provides prognostic information, corresponding to Gleason score (GS), that could help to identify patients with aggressive PCa.
MDxHealth to Present Results from Epigenetic Prostate Test to Identify Aggressive Prostate Cancer at the ASCO Genitourinary Cancers Symposium 2014
GlobeNewswire - Wed Jan 29, 1:08AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will present results from an important study involving the development of their prostate cancer (PCa) aggressiveness test at the ASCO Genitourinary Cancers Symposium 2014 in San Francisco, California, USA (January 30 - February 1, 2014).
MDxHealth Announces Agreement with Teva Pharmaceuticals for Commercialization of Two Cancer Tests in Israel
GlobeNewswire - Thu Jan 23, 4:14AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has signed an exclusive agreement with Teva Pharmaceuticals Ltd. for commercialization of ConfirmMDx for Prostate Cancer and PredictMDx for Glioblastoma tests in Israel. ConfirmMDx provides physicians with actionable information that helps improve patient care, particularly the avoidance of unnecessary repeat prostate biopsies. The PredictMDx test is used to identify glioma patients who have methylation of the MGMT (O6-Methylguanine-DNA Methyltransferase) gene. In clinical studies, these patients have shown the potential to respond better to certain chemotherapeutic drugs.
MDxHealth Signs Agreement With Stratose(R) to Expand Insurance Coverage for ConfirmMDxTM for Prostate Cancer Test
Marketwire - Tue Sep 03, 1:31AM CDT
MDxHealth SA (EURONEXT BRUSSELS: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, today announced that it has entered into an agreement with Stratose, one of the largest healthcare PPO network providers in the U.S. The agreement provides Stratose's 12.4 million member network with access to ConfirmMDx for Prostate Cancer testing.
